IL1B and rheumatoid arthritis: Canakinumab, a human IgG1 anti-IL-1β monoclonal antibody initially approved for rheumatoid arthritis, has been successfully repurposed for MWS, an autoinflammatory rare disorder caused by increased IL-1 (9).